Agreement – Eurocine Vaccines extends its product portfolio


Eurocine Vaccines AB has decided to evaluate a diagnostic test of chlamydia antibodies in blood as an extension of its portfolio and has widened the license agreement with Spixia Biotechnology AB to also include diagnostic tests of chlamydia.

Watch Video:

Chlamydia is a sexually transmitted bacterial disease that often leads to involuntary infertility in women (read more). There is currently no prophylactic vaccine against chlamydia on the market and Eurocine Vaccines is developing a vaccine candidate based on a patented protein (read more). At the same time, there is a need for better diagnostic tests in both Europe and the United States, to investigate if patients have or have undergone the disease and carry antibodies (Woodhall et al., Lancet Infect Dis 2018). According to our market analysis, such an improved test could be widely used for studies focusing on public health, for example to understand what proportion of the population has had chlamydia infection (so-called seroepidemiological studies), and to understand if previous chlamydia infection can be the cause of infertility. Therefore, Eurocine Vaccines has widened the license agreement with Spixia Biotechnology to also include a diagnostic test of chlamydia in order to evaluate it as an extension of its portfolio.

Through the ongoing work to develop the manufacturing process for the active protein in the chlamydia vaccine candidate, which will primarily be used in further preclinical and clinical studies in the ongoing vaccine development, the company sees the opportunity for an additional application. The same protein can be the used for both the prophylactic vaccine and a diagnostic test of antibodies against chlamydia. This provides significant synergies in the form of documentation, process development, and protein manufacture, creating the opportunity for more products based on the same research and development.

In the next step, initial experiments will be performed to evaluate a diagnostic test based on the active protein and how a future diagnostic product can best be designed. These trials are expected to be completed during the second quarter of 2022.

“It is completely in line with our strategy to actively seek additional opportunities to innovatively create added value based on our investments. Although the market potential is smaller for a diagnostic tool than for a vaccine, it is all about how to best contribute to modern healthcare based on our research and development”, comments Dr. Karl Ljungberg, Director of preclinical development.


I want to grow my online platform to create awareness about ethical consumerism, environmentalism, and the plant-based lifestyle. My main mission is to share information that empowers people to make better choices and create a VEG NEW WORLD :)

Your support is vital and is helping me share the collected information with thousands of readers and viewers. I try to deliver exclusive stories and relevant content in a challenging commercial environment. Your contribution helps me to cover the costs that my service requires. Please consider contributing (no matter how small) to keep the information flowing so you can remain informed and have life changing interviews and stories to share.

Related articles

Niles + Chaz Unveils Vegan Haircare Line for Kids with Mixed Textured Hair

  Niles + Chaz is launching a vegan, organic, cruelty-free, nut-free,...

Hain Celestial Appoints Chris Jenkins as Global Impact Leader

  Appointment Reinforces Hain's Commitment to Advance its Global Impact...

Cresilon Announces Global Distribution Agreement for VETIGEL with Covetrus

  Revolutionary hemostatic gel for veterinary surgeons available in the...

Paving the Way for a Vegan Europe: The Plant-Based Manifesto and Its Vision for 2050

  The European Vegetarian Union (EVU) has launched a groundbreaking...
Betty Tűndik
Betty Tűndik
Hi everyone! Nice to e-meet you! Here are a few things you should know about me. I am a conscientious, open-minded, adaptable to new experiences, and ambitious Business Development Manager with a Bachelor's Degree in Economics - Banking, Finance, and Accountancy. Through my studies, I've also obtained many naturopathic and nutrition degrees as well. Part-time jobs have added marketing, network marketing, event management, and store management skills to my experience throughout my career. Throughout my career, I have also been a Hotel Manager and owned a Bar/Restaurant & Internet Cafe. My online marketing and social media interactivity experience was gained when I and my husband started a business with an online/organic webshop & healthy lifestyle consultancy. I've improved my English at Cambridge Academy of English - 2003, in Cambridge. I live a conscious lifestyle, and try to protect the ecosystem. Animal lover and capable of helping others without judgment or negative reactions, this is thanked my knowledge in holistic therapies and the naturopathy courses I've followed. I cannot leave for my spiritual growth and the continuous development in alternative and holistic therapies, so I'm learning at Kyron School of New Consciousness, receiving a Bio Energo-therapist diploma. Thanks to all my experiences I've decided to venture into publishing and writing, while also continuing to learn many new things daily. I hope you enjoy reading my hand-picked news and check back for my weekly articles.